USPTO serial 79408532
STAGEOSIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 5, 2025
- Examiner
- SCHLEGELMILCH, JONATHON A
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with STAGEOSIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ronald M. Kachmarik
Ronald M. Kachmarik Cooper Legal Group LLC1388 Ridge Road, Unit 1Hinckley, OH 44233United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic preparations for industrial and scientific use; chemical reagents for industrial use; chemical reagents for scientific use | ACTIVE | — |
| 005 | Pharmaceutical preparations for the diagnosis, prevention and treatment of metabolic, hepatic and oncological diseases and disorders; diagnostic preparations and diagnostic biomarker reagents for medical use; medical diagnostic testing materials for medical use namely, diagnostic reagents and assays for testing of bodily fluids; blood and blood-derived samples for medical use, namely, blood substitutes for human use, blood plasma, serum and other blood-derived biological samples | ACTIVE | — |
| 009 | Downloadable and recorded software for use in the management of cancer, metabolic diseases and liver diseases, namely, software for creating customized care plans for patients, for managing patient data, for providing clinical decision support information and analytics, for managing patient medications, and for providing reporting and analytics relating to patient care, and for use in research and development of new pharmaceutical products for others, namely, software for managing, analyzing and reporting on clinical trial data; downloadable software applications for use in diagnosing medical conditions; scientific apparatus and instruments for recording, processing, reproduction and transmission of data, namely electronic data loggers and recorders; data processing equipment | ACTIVE | — |
| 010 | Medical apparatus, instruments and equipment namely, DNA, RNA and protein analysis apparatus, DNA, RNA and protein quantifiers, medical devices for measuring DNA, RNA, biochemical and physical parameters, namely, concentration of biomarkers and blood analyzers for evaluation of metabolic, hepatic and oncological diseases and disorders; instruments and tools for medical diagnosis, namely diagnostic medical devices for diagnosis of metabolic, hepatic and oncological diseases and disorders, blood analysis apparatus, DNA and RNA analysis apparatus, gene analyzers, medical devices for measuring biochemical and physical parameters, namely, concentration of biomarkers relating to the evaluation of metabolic, hepatic and oncological diseases and disorders, and blood analyzers for evaluation of metabolic, hepatic and oncological diseases and disorders | ACTIVE | — |
| 042 | Scientific and technological services, namely research in the medical, biomedical, and chemical fields, for the diagnosis, prevention and treatment of metabolic, hepatic and oncological diseases and disorders; biological research; clinical research and medical research in the field of diagnosis, prevention and treatment of metabolic, hepatic and oncological diseases and disorders; industrial analysis and industrial research services in the field of pharmacy; design and development of computer hardware and software; programming for computers | ACTIVE | — |
| 044 | Medical analysis for the diagnosis, prevention and treatment of metabolic, hepatic and oncological diseases and disorders; medical analysis of blood samples; assistance services in the fields of medicine and health care; medical information; provision of medical information | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by GENFIT
- Other trademarks owned by GENFIT
- Other trademarks owned by GENFIT
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named STAGEOSIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 16, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 30, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 29, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 5, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 15, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 15, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 5, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 5, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 5, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 19, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 17, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 17, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 31, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 19, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 16, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 16, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 16, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 10, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 10, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 22, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 21, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 17, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 5, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 31, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |